TITLE

MANAGEMENT OF UPPER GASTROINTESTINAL CANCERS: HOW ARE WE DOING?

PUB. DATE
April 2004
SOURCE
Gut;Apr2004 Supplement 3, Vol. 53, pA108
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
This article focuses on the management of upper gastrointestinal cancers by medical personnel. "NHS Cancer Plan" with earlier diagnosis and treatment of cancers is more so important in upper gastrointestinal (GI) cancers where the prognosis remains worse despite advances in treatment and hence a "very early diagnosis" is the key. 65 patients, 28 females were identified. The mean age was 71 years, range 43-86 for males and 75 years range, 54-96 for females. 58 patients were directly referred from GPs whereas 7 were in hospital referrals. Despite majority 86% of patients having had a diagnosis within 4 weeks only 45% were resected.
ACCESSION #
13219237

 

Related Articles

  • Australia's National Bowel Cancer Screening Program: does it work for Indigenous Australians? Christou, Aliki; Katzenellenbogen, Judith M; Thompson, Sandra C // BMC Public Health;2010, Vol. 10 Issue 1, p373 

    Background: Despite a lower incidence of bowel cancer overall, Indigenous Australians are more likely to be diagnosed at an advanced stage when prognosis is poor. Bowel cancer screening is an effective means of reducing incidence and mortality from bowel cancer through early identification and...

  • A phase II study of combined chemotherapy with methotrexate, 5-fluorouracil, and low-dose cisplatin (MFP) for histologically diffuse-type advanced and recurrent gastric cancer (KDOG9501). Nakayama, Norisuke; Koizumi, Wasaburo; Tanabe, Satoshi; Sasaki, Tohru; Saigenji, Katsunori // Gastric Cancer;Sep2006, Vol. 9 Issue 3, p185 

    Histologically diffuse-type gastric cancer is well known to have a poor prognosis and is often complicated with abdominal and pleural effusions. We evaluated the efficacy of a low dose of cisplatin combined with methotrexate and 5-fluorouracil (MFP therapy) in diffuse-type advanced gastric...

  • Diffuse Sclerosing Variant of Papillary Thyroid Carcinoma with Concomitant Thyrotoxicosis: A Case Report and Literature Review. Chan, Jessie Y. W.; Tsui, David K. K.; Polly Tsui; Tang Chung Ngai // Surgical Science;Mar2014, Vol. 5 Issue 3, p117 

    Diffuse sclerosing variant of papillary thyroid carcinoma (DSVPC) is a rare variant of conventional papillary thyroid carcinoma which was first reported in 1985. It appears to be more aggressive than conventional type of papillary thyroid carcinoma. We present a case in a 14-year-old girl who...

  • Prostate Cancer: An Evolving Paradigm. Caso, Jorge R.; Mouraviev, Vladimir; Tsivian, Matvey; Polascik, Thomas J.; Moul, Judd W. // Journal of Endourology;May2010, Vol. 24 Issue 5, p805 

    AbstractSince at least the early 1990s, stage and risk migration have been seen in patients with prostate cancer, likely corresponding to the institution of prostate specific antigen (PSA) screening in health systems. Preoperative risk factors, including PSA level and clinical stage, have...

  • Astonishing Facts and Figures on Brain Cancer.  // Art of Healing;Jun/Aug2014, Vol. 2 Issue 47, p11 

    The article offers information on the facts and figures about brain cancer. It notes that brain cancer is the leading cause of death among children aged under 15. It also outlines the general condition, causes, and symptoms of brain cancer. Moreover, it also mentions the challenging nature of...

  • Outpatient Theraapy. Alexander, Walter // Dermatology Times;Jul2003, Vol. 24 Issue 7, p32 

    Focuses on the safety and efficacy of outpatient, self-administered chemobiotherapy for patients with metastatic melanoma in the U.S. Option for patients with metastatic melanoma; Design of the therapeutic method; Advantage of the method used in the prognosis of cancer patients.

  • New test improved prostate cancer risk assessment.  // Hem/Onc Today;7/10/2013, Vol. 14 Issue 13, p8 

    The article reports that the genomic screening test called Oncotype DX has improved the ability to predict disease aggressiveness among patients at risk for prostate cancer.

  • Epidemic, what epidemic? Gombe, Spring // New Internationalist;Nov2003, Issue 362, p20 

    Focuses on the sleeping sickness epidemic in Africa. Investigation on the cause of the disease; Challenges faced by medical personnel in diagnosing and treating the condition; Drugs used to control the symptoms.

  • Risk factors for delay in symptomatic presentation: a survey of cancer patients. Forbes, L J L; Warburton, F; Richards, M A; Ramirez, A J // British Journal of Cancer;7/29/2014, Vol. 111 Issue 3, p581 

    Background:Delay in symptomatic presentation leading to advanced stage at diagnosis may contribute to poor cancer survival. To inform public health approaches to promoting early symptomatic presentation, we aimed to identify risk factors for delay in presentation across several...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics